NCT04424966 - Infigratinib in Recurrent High-Grade Glioma Patients | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 21, 2020

Primary Completion Date

April 27, 2023

Study Completion Date

April 27, 2023

Conditions

GliomaGlioblastomaGBM

Interventions

DRUG

Infigratinib

The Phase 0 study will include treatment of recurrent high-grade glioma participants with 125 mg of infigratinib 7 days prior to surgical resection. Participants with tumors demonstrating PK-response will continue treatment with the same dose continuously for 21 days in 28-day cycles after surgery.

Trial Locations (3)

85013

St. Joseph's Hospital and Medical Center, Phoenix

85224

Chandler Regional Medical Center, Chandler

85251

HonorHealth Scottsdale Osborn Medical Center, Scottsdale